Strata Skin Sciences (SSKN) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Strata Skin Sciences (NASDAQ:SSKN) from a sell rating to a hold rating in a report released on Thursday.

According to Zacks, “Strata Skin Sciences, Inc. is a medical technology company which focused on the dermatology market. Its products include the XTRAC laser(R) and VTRAC(R) excimer lamp systems for treatment of psoriasis, vitiligo and other skin conditions as well as the MelaFind (R) system used for identification and management of melanoma skin cancer. Strata Skin Sciences, Inc., formerly known as MELA Sciences, Inc., is based in Horsham, Pennsylvania. “

Several other research analysts also recently issued reports on SSKN. ValuEngine downgraded Strata Skin Sciences from a sell rating to a strong sell rating in a research note on Sunday, December 31st. HC Wainwright reaffirmed a buy rating and issued a $7.00 price objective on shares of Strata Skin Sciences in a research note on Friday, November 10th.

Strata Skin Sciences (SSKN) traded down $0.04 during trading on Thursday, hitting $1.44. The stock had a trading volume of 65,400 shares, compared to its average volume of 175,878. Strata Skin Sciences has a one year low of $1.06 and a one year high of $5.40. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.64 and a quick ratio of 1.07. The firm has a market capitalization of $5.86, a P/E ratio of -0.19 and a beta of 0.41.

Strata Skin Sciences (NASDAQ:SSKN) last released its quarterly earnings data on Thursday, November 9th. The medical device company reported ($0.76) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.08). Strata Skin Sciences had a negative net margin of 56.06% and a negative return on equity of 38.57%. equities research analysts predict that Strata Skin Sciences will post -8.45 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://sportsperspectives.com/2018/01/15/strata-skin-sciences-sskn-upgraded-by-zacks-investment-research-to-hold.html.

Strata Skin Sciences Company Profile

STRATA Skin Sciences, Inc, formerly MELA Sciences, Inc, is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging.

Get a free copy of the Zacks research report on Strata Skin Sciences (SSKN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strata Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strata Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply